Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Guzelkucuk Z, Isık M, Ozcan AS, Demirkan TH, Yaralı N

Imatinib-related interstitial lung disease.

British journal of haematology. 2018;180(6):780

Choi MH, Jung JI, Chung WD, Kim YJ, Lee SE, Han DH, Ahn MI, Park SH

Acute pulmonary complications in patients with hematologic malignancies.

Radiographics : a review publication of the Radiological Society of North America, Inc. 2014;34(6):1755-68

Eşkazan AE, Salihoğlu A, Erturan S, Soysal T

Interstitial pneumonitis in a patient with chronic myeloid leukemia.

Turkish journal of haematology : official journal of Turkish Society of Haematology. 2013;30(4):435-6

Dao K, Védy D, Lopez J, Staneczek O, Buclin T, Livio F

Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data.

International journal of hematology. 2013;97(2):299-300

Nakashima S, Kakugawa T, Motomura H, Hirano K, Sasaki E, Nagata Y, Kinoshita A, Sakamoto N, Ishimatsu Y, Mukae H, Kohno S

Development of imatinibmesylate-induced interstitial lung disease 2 weeks after discontinuation of the treatment: a case report.

Multidisciplinary respiratory medicine. 2012;7(1):48

Delomas T, Darné C, Besson C

Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib.

Leukemia & lymphoma. 2012;53(2):332-3

Stakhina OV, Turkina AG, Kostina IE, Kochkareva IuB

[A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].

Terapevticheskii arkhiv. 2010;82(2):59-61

Carrillo-Esper R, Morales-Victorino N

[Imatinib-induced pulmonary toxicity].

Gaceta medica de Mexico. 2009;145(5):437-9

Ohnishi K, Sakai F, Kudoh S, Ohno R

Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate.

Leukemia. 2006;20(6):1162-4

Yamasawa H, Sugiyama Y, Bando M, Ohno S

Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis.

Respiration; international review of thoracic diseases. 2008;75(3):350-4

Rajda J, Phatak PD

Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy.

American journal of hematology. 2005;79(1):80-1

Grimison P, Goldstein D, Schneeweiss J, Murray N

Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge, and potential causative mechanisms.

Internal medicine journal. 2005;35(2):136-7

Ma CX, Hobday TJ, Jett JR

Imatinib mesylate-induced interstitial pneumonitis.

Mayo Clinic proceedings. 2003;78(12):1578-9

Rosado MF, Donna E, Ahn YS

Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(16):3171-3

Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, Espérou H, Socié G, Calvo F, Gluckman E, Ribaud P, Rousselot P, Tazi A

Hypersensitivity pneumonitis related to imatinib mesylate.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002;20(20):4271-2